| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of MK-7337 is alpha‑synuclein (alpha‑Syn), a protein that aggregates to form Lewy bodies, which are pathological hallmarks of Parkinson's disease (PD) and other synucleinopathies. MK-7337 binds to these aggregated forms of alpha‑synuclein, allowing for their detection. The PET tracer crosses the blood‑brain barrier and selectively binds to alpha‑synuclein deposits, enabling imaging of protein aggregation in vivo.
|
|---|---|
| ln Vitro |
In vitro, MK-7337 is evaluated for its binding affinity to alpha‑synuclein fibrils. A standard assay involves immobilizing recombinant alpha‑synuclein fibrils on a microplate or filter. MK-7337 is incubated with the fibrils at various concentrations (0.1-100 nM). After washing to remove unbound ligand, the amount of bound MK-7337 is quantified, either by using a radiolabeled version (e.g., ¹¹C‑MK‑7337) and measuring radioactivity, or by using a fluorescently labeled derivative. The binding affinity (Kd) is calculated from saturation binding curves. The selectivity of MK-7337 for alpha‑synuclein over other amyloidogenic proteins (e.g., amyloid‑beta (Abeta) and tau) is also assessed.
|
| ln Vivo |
Cell-based assays for MK-7337 are not typical, as it is a PET tracer for imaging aggregated proteins, which are non‑cellular deposits. However, cellular models of alpha‑synuclein aggregation (e.g., HEK293 cells overexpressing alpha‑synuclein with aggregation‑prone mutations) can be used to evaluate the cellular uptake and intracellular binding of the tracer. Cells are incubated with ¹¹C‑MK‑7337, and the accumulation of radioactivity is measured in a gamma counter. Confocal microscopy with fluorescently labeled MK-7337 can be used to visualize the co‑localization of the tracer with alpha‑synuclein aggregates within the cells.
|
| Enzyme Assay |
In vivo animal experiments for MK-7337 are performed in mouse or rat models of alpha‑synuclein aggregation, such as mice injected with alpha‑synuclein pre‑formed fibrils (PFFs) or transgenic mice overexpressing human alpha‑synuclein (e.g., Thy1‑aSyn mice). The compound, labeled with ¹¹C (half‑life ~20 minutes), is administered intravenously (e.g., via the tail vein) at a tracer dose (typically sub‑pharmacological, e.g., 10-50 MBq per mouse). The animal is placed in a small‑animal PET scanner, and dynamic imaging is performed for 60-90 minutes. The accumulation of the tracer in the brain, particularly in regions known to develop alpha‑synuclein pathology (e.g., substantia nigra, striatum, cortex), is measured. The specificity of binding is confirmed by blocking experiments with an excess of unlabeled MK-7337 or by comparing binding in wild‑type vs. alpha‑synuclein‑expressing animals.
|
| Cell Assay |
Pharmacokinetic data for MK-7337 are derived from PET studies. The unlabeled compound has a molecular weight of 455.5 g/mol and a molecular formula of C24H2₅N₉O. It appears as an off‑white to light yellow solid powder. The compound is typically stored at -20degC, protected from light. It is soluble in DMSO and organic solvents. The purity is >98% from commercial suppliers.
|
| Animal Protocol |
The toxicity of MK-7337 has not been fully characterized. As a research chemical used as a PET tracer, the compound is administered in very low (tracer) doses, so its pharmacological and toxicological risks are minimal. Standard safety precautions for handling radioactive materials apply when using the ¹¹C‑labeled version. The unlabeled compound may be harmful if swallowed, inhaled, or absorbed through the skin. It may cause skin and eye irritation. It should be handled in a well-ventilated area (fume hood) with appropriate PPE.
|
| ADME/Pharmacokinetics |
Additional information: The compound has a CAS number of 3056154-69-6 and is also known as an alpha‑synuclein PET ligand. It is for research use only and is not for human or veterinary use. It is used as a research tool for the development of imaging agents for Parkinson's disease and other neurodegenerative disorders. Synonyms include MK-7337, 3056154-69-6.
|
| References |
| Molecular Formula |
C24H25N9O
|
|---|---|
| Molecular Weight |
455.52
|
| CAS # |
3056154-69-6
|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1953 mL | 10.9765 mL | 21.9529 mL | |
| 5 mM | 0.4391 mL | 2.1953 mL | 4.3906 mL | |
| 10 mM | 0.2195 mL | 1.0976 mL | 2.1953 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
